Suggested remit: To appraise the clinical and cost effectiveness of icosapent ethyl within its marketing authorisation for preventing cardiovascular events due to elevated triglycerides.
 
Status In progress
Decision Selected
Process STA 2018
ID number 3831

Provisional Schedule

Expected publication 20 July 2022

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd

Stakeholders

Companies sponsors Amarin Corporation (Icosapent ethyl)
Others Department for Health and Social Care
  NHS England
  Welsh Government
Patient carer groups HEART UK
Professional groups Association of British Clinical Diabetologists
  British Cardiovascular Society
  Royal College of Physicians
Associated guideline groups National Guideline Alliance
Associated public health groups None
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Heart Group

Timeline

Key events during the development of the guidance:

Date Update
04 May 2022 Committee meeting: 3
28 March 2022 - 19 April 2022 Draft guidance: 2
08 March 2022 Committee meeting: 2
01 February 2022 - 22 February 2022 Draft guidance
11 January 2022 Committee meeting: 1
24 May 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in adults with elevated triglycerides. Following on from a request received from the company, the timelines for this appraisal have been revised in order to facilitate a comprehensive and robust submission.
15 February 2021 Invitation to participate
15 February 2021 In progress. In progress.
25 September 2020 - 23 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual